restructuring

After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly. 

As part of the deal with an institutional investor, Interpace's royalty and milestone obligations will also be terminated. 

The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.

As part of a restructuring and cost reduction plan the firm also reduced the principle of its 2016 convertible note by about half.

The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.

The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.

The company reported drops in revenues for both its human health and environmental health units, blaming challenging market conditions for the decreases.

The company beat analysts' consensus estimates on both the top and bottom lines as its molecular diagnostics sales rose 9 percent at constant exchange rates.

The company said the diagnostics unit will be focused on reproductive health, diagnostics for emerging markets, and applied genomics.

Olink Proteomics will focus on developing protein biomarker discovery products while Olink Bioscience will work on other technologies arising from its IP portfolio.